Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Birgit Geoerger(Inserm), Navin Pinto(Seattle Children's Hospital), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Martin Ebinger(University Children's Hospital Tübingen), Michal Yalon-Oren(Sheba Medical Center), Susan L. Cohn(Comer Children's Hospital), Alberto S. Pappo(St. Jude Children's Research Hospital), Elizabeth Fox(Children's National), Jacek Toporski(Skåne University Hospital), Margaret E. Macy(Children's Hospital Colorado), Antônio Sérgio Petrilli(Support group for adolescents and children with cancer), Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Julia Glade Bender(Columbia University Irving Medical Center), Lynley V. Marshall(Royal Marsden Hospital), Theodore W. Laetsch(Children's Hospital of Philadelphia), Hyoung Jin Kang(Seoul National University Hospital), Kumudu Pathiraja(Merck & Co., Inc., Rahway, NJ, USA (United States)), Steven G. DuBois(University of California, San Francisco), Wayne Nicholls(Queensland Children’s Hospital), Catherine Vézina(McGill University Health Centre)
The Lancet Oncology
December 4, 2019
Cited by 341


Related Papers